Register Login
Register to leave comments
  • News bot Aug. 14, 2026, 11:06 a.m.

    📋 TVARDI THERAPEUTICS, INC. (TVRD) - Financial Results

    Filing Date: 2026-08-14

    Accepted: 2026-08-14 07:05:24

    Event Type: Financial Results

    Event Details:

    TVARDI THERAPEUTICS, INC. (TVRD) Reports the reporting period Financial Results TVARDI THERAPEUTICS, INC. (TVRD) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: $4
    • EPS: Not disclosed
    • Cash and equivalents: 15765
      • generation STAT3 inhibitor, TTI
      • 109, confirming prodrug design, improved tolerability and pharmacodynamic evidence of STAT3 target engagement. oTTI
      • equivalent exposure with improved tolerability and, across the active dose range, reductions in cellular and humoral immune populations known to correlate with UC disease severity. ·Selected UC as the initial disease indication for TTI
        • targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive uncontrolled proliferation, survival and immune dysregulation. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The Company is conducting clinical trials with TTI-109 in healthy volunteers and TTI-101 in hepatocellular carcinoma (NCT0544
        • targeting STAT3 to treat inflammatory and proliferative diseases, today reported its financial and operating results for the second quarter ended June 30, 2026

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Current Assets Prepaid Expenses Other Current Assets 1.30K 727.00 $577.00 +79.37%
    Current Assets Property Equipment Net 36.00 52.00 $-16.00 -30.77%
    Current Assets Intangible Assets Net 291.00 322.00 $-31.00 -9.63%
    Current Assets Operating Lease Right Of Use Assets 104.00 144.00 $-40.00 -27.78%
    Current Liabilities Accounts Payable 4.64K 3.22K $1.42K +44.08%
    Operating Expenses Loss From Operations 8.87K 13.68K $-4.81K -35.17%
    Operating Expenses Interest Income 377.00 419.00 $-42.00 -10.02%
    Operating Expenses Other Income Net 12.66K 12.66K $0.00 +0.00%
    Prepaid Expenses and Other Current Assets 727.00 727.00 $0.00 +0.00%
    Property and Equipment, Net 52.00 52.00 $0.00 +0.00%
    Intangible Assets, Net 322.00 322.00 $0.00 +0.00%
    Accounts Payable 3.22K 3.22K $0.00 +0.00%
    Operating Lease Liabilities 116.00 116.00 $0.00 +0.00%
    Loss from Operations 8.87K 13.68K $-4.81K -35.17%
    Interest Income 377.00 419.00 $-42.00 -10.02%
    Other Income, Net 12.66K 12.66K $0.00 +0.00%
    Net Loss 4.17K 13.26K $-9.09K -68.58%

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: TVARDI THERAPEUTICS, INC.
    • Ticker Symbol: TVRD

Search

News categories